Corrigendum to “Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer” [Cancer Lett. 396 (2017) 155–166]

Cancer Letters xxx (2017) 1

Contents lists available at ScienceDirect

Cancer Letters journal homepage: www.elsevier.com/locate/canlet

Corrigendum

Corrigendum to “Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer” [Cancer Lett. 396 (2017) 155e166] Kyung Hee Jung a, 1, Il-Kyu Choi b, c, 1, Hee-Seung Lee a, Hong Hua Yan a, Mi Kwon Son a, Hyo Min Ahn b, JinWoo Hong b, Chae-Ok Yun b, **, Soon-Sun Hong a, * a b c

Department of Biomedical Sciences, College of Medicine, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 400-712, Republic of Korea Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, 133-791, Seoul, Republic of Korea Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA

The authors regret that the grant number was mentioned incorrectly in the original article and the correct Grant number is “2015M3A9C4075818”. The authors would like to apologise for any inconvenience caused.

DOI of original article: http://dx.doi.org/10.1016/j.canlet.2017.03.009. * Corresponding author. ** Corresponding author. E-mail addresses: [email protected] (C.-O. Yun), [email protected] (S.-S. Hong). 1 These authors have contributed equally to this work. http://dx.doi.org/10.1016/j.canlet.2017.06.019 0304-3835/© 2017 Elsevier B.V. All rights reserved.

Please cite this article in press as: K.H. Jung, et al., Corrigendum to “Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer” [Cancer Lett. 396 (2017) 155e166], Cancer Letters (2017), http://dx.doi.org/10.1016/ j.canlet.2017.06.019